Physician

Travis J Rutland, MD

According to 2025 Medicare claims, Travis Rutland, MD (NPI: 1518922087) practices gastroenterology in the Dothan, AL market, with the plurality of this provider's patient population coming from Houston, AL. This provider's primary affiliated billing organization is GUT PC (NPI: 1073566006; TIN: 20-2904686) and primary practice location at 36305-1156. Rutland is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Rutland's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 972 traditional Medicare patients, billed 15,547 HCPCS/CPT codes, and received $407,676 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 5,489 prescription claims across 1,160 beneficiaries totaling $4,792,405 in drug costs, led by Stelara (Ustekinumab). 2019 DME data shows 24 claims. Open Payments data shows 201 records totaling $153,124. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $1,123,756 to $4,792,405. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,211	39,172	$630,026
2016	2,012	53,466	$621,274
2017	1,718	45,054	$529,022
2018	1,421	40,571	$496,224
2019	1,428	32,906	$498,321
2020	1,255	23,986	$509,245
2021	1,215	24,639	$489,221
2022	1,152	21,783	$478,579
2023	1,077	19,174	$411,967
2024	972	15,547	$407,676

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	892	4,567	$1,123,756
2016	936	4,733	$923,753
2017	949	4,720	$737,379
2018	860	4,572	$957,826
2019	856	4,113	$907,297
2020	857	4,307	$1,242,377
2021	980	4,705	$1,420,982
2022	1,090	4,972	$2,344,262
2023	1,150	5,134	$3,324,943
2024	1,160	5,489	$4,792,405

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	60	$3,882
2016	N/R	34	$2,445
2017	N/R	19	$548
2018	N/R	23	$645
2019	N/R	24	$651
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	185	185	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	268	310	$86
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	211	1,291	$46
43239	Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope	273	291	$38
99439	Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month	208	2,229	$36

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Stelara	Ustekinumab	96	4,740	$2,702,375
Linzess	Linaclotide	416	19,730	$348,148
Creon	Lipase/Protease/Amylase	97	3,145	$280,117
Humira(Cf) Pen	Adalimumab	23	756	$185,427
Xifaxan	Rifaximin	59	1,536	$175,575

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	196	$132,508	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	5	$20,617	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Travis J. Rutland, MD?

Tedicare shows public-source Medicare data for Travis J. Rutland, MD (NPI 1518922087), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Travis J. Rutland, MD have ACO affiliation data?

Travis J. Rutland, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Travis J. Rutland, MD?

Travis J. Rutland, MD is linked to GUT PC (billing NPI 1073566006) in the available physician profile data.

Does Travis J. Rutland, MD have Open Payments data?

Travis J. Rutland, MD has 201 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.